[ad_1]
However, ibogaine is complex to synthesize, and like many natural products, not enough of the compound can be extracted from its natural source for …
[ad_2]
Source link
Psychedelics re-engineered for potential use in the clinic
[ad_1]
Ibogaine is a naturally occurring alkaloid found in the West African rainforest shrub Tabernanthe iboga (Fig. 1). Preclinical data and small-scale …
[ad_2]
Source link
Non-hallucinogenic ibogaine could treat addiction and depression
[ad_1]
A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.
A non-hallucinogenic version of the psychedelic drug ibogaine, with the potential for treating addiction, depression and other psychiatric disorders, has been developed by researchers at the University of California (UC), Davis, US.
“Psychedelics are some of the most powerful ...
Ibogaine inspires potential neuropsychiatric treatment
[ad_1]
By systematically tweaking the structure of the psychedelic compound ibogaine, chemists have created a molecule that may someday find use as a treatment for neuropsychiatric disorders, including depression and addiction. The compound, which the researchers call tabernanthalog, also has a simpler structure than ibogaine, making it easier to synthesize.
Researchers in David E. Olson’s lab at the University of California, Davis have been exploring ...
Mind Cure Health Begins Research Into Psychedelic Compounds
[ad_1]
Mind Cure Health (CSE: MCUR) has reached a milestone, with the company this morning announcing its translational research program that will initially focus on the compounds of psilocybin, ibogaine, and ketamine. Research into the compounds is said to be largely focused on the treatment of physical and psychological pain and related mental health illnesses.
Translational research in layman terms is multidisciplinary and involves applying lab research ...